Shares of Emergent Biosolutions Inc (NYSE:EBS) hit a new 52-week high on Friday . The stock traded as high as $64.64 and last traded at $64.70, with a volume of 10270 shares changing hands. The stock had previously closed at $60.94.

EBS has been the subject of several recent analyst reports. Chardan Capital increased their target price on Emergent Biosolutions from $60.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, September 4th. Zacks Investment Research downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Monday, August 20th. Cantor Fitzgerald set a $62.00 target price on Emergent Biosolutions and gave the company a “buy” rating in a research note on Tuesday, August 28th. Cowen restated a “hold” rating and set a $49.00 target price on shares of Emergent Biosolutions in a research note on Wednesday, August 29th. Finally, Wells Fargo & Co set a $61.00 target price on Emergent Biosolutions and gave the company a “hold” rating in a research note on Friday, August 10th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $61.63.

The company has a market cap of $3.01 billion, a price-to-earnings ratio of 32.24, a P/E/G ratio of 1.27 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.59 and a quick ratio of 4.15.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.19. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The firm had revenue of $220.20 million during the quarter, compared to the consensus estimate of $208.94 million. During the same quarter in the prior year, the company earned $0.13 EPS. The firm’s revenue for the quarter was up 118.5% compared to the same quarter last year. equities analysts forecast that Emergent Biosolutions Inc will post 2.37 earnings per share for the current year.

In other Emergent Biosolutions news, CEO Daniel Abdun-Nabi sold 90,776 shares of the firm’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $60.18, for a total value of $5,462,899.68. Following the completion of the sale, the chief executive officer now owns 257,343 shares in the company, valued at approximately $15,486,901.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronald Richard sold 7,893 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $60.02, for a total value of $473,737.86. Following the completion of the sale, the director now owns 21,063 shares of the company’s stock, valued at approximately $1,264,201.26. The disclosure for this sale can be found here. Insiders sold a total of 165,087 shares of company stock valued at $9,597,369 in the last quarter. Corporate insiders own 16.50% of the company’s stock.

Several hedge funds have recently made changes to their positions in EBS. Summit Trail Advisors LLC lifted its position in shares of Emergent Biosolutions by 4,093.4% in the 1st quarter. Summit Trail Advisors LLC now owns 1,378,959 shares of the biopharmaceutical company’s stock worth $1,379,000 after acquiring an additional 1,346,075 shares during the period. BlackRock Inc. lifted its position in shares of Emergent Biosolutions by 20.2% in the 2nd quarter. BlackRock Inc. now owns 5,372,711 shares of the biopharmaceutical company’s stock worth $271,268,000 after acquiring an additional 901,882 shares during the period. Matarin Capital Management LLC bought a new stake in shares of Emergent Biosolutions in the 1st quarter worth approximately $18,524,000. Prudential Financial Inc. raised its holdings in shares of Emergent Biosolutions by 446.1% in the 1st quarter. Prudential Financial Inc. now owns 416,921 shares of the biopharmaceutical company’s stock worth $21,951,000 after buying an additional 340,578 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Emergent Biosolutions by 29.6% in the 1st quarter. Millennium Management LLC now owns 917,065 shares of the biopharmaceutical company’s stock worth $48,283,000 after buying an additional 209,581 shares in the last quarter. Institutional investors own 83.01% of the company’s stock.

About Emergent Biosolutions (NYSE:EBS)

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Further Reading: Technical Analysis of Stocks and What It Means

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.